Laboratory Features in LDGL Patients With a Low Number of GL (<2,000/μL) as Compared With Findings Detected in Cases With Typical Disorder
| Variable . | Patients With Low GL Count . | Typical LDGL Patients . | ||
|---|---|---|---|---|
| . | (<2,000/μL) . | (>2,000/μL) . | ||
| . | Observed . | % . | Observed . | % . |
| Hemoglobin (<10 g/dL) | 5/11 | 45.4 | 37/151 | 24.5 |
| WBC (>5,000/μL) | 1/11 | 9.0 | 126/151 | 83.4 |
| Severe neutropenia | ||||
| (<500/μL) | 4/11 | 36.3 | 55/149 | 36.9 |
| Platelets (<100,000/μL) | 1/11 | 9.0 | 12/134 | 8.9 |
| Bone marrow infiltration | 4/7 | 57.1 | 90/116 | 77.5 |
| Clonal TCR (CD3+ LDGL) | 9/9 | 100 | 115/127 | 90.6 |
| Clonal NK populations (CD3− LDGL) | ND | 12/19 | 63.1 | |
| Cytogenetics abnormality | 0/6 | 0 | 15/119 | 12.6 |
| Coomb's test | 0/6 | 0 | 3/71 | 4.2 |
| Rheumatoid factor | 1/10 | 10.0 | 34/72 | 47.2 |
| Antinuclear antibodies | 3/10 | 30.0 | 23/59 | 38.9 |
| Hypergammaglobulinemia | 3/6 | 50.0 | 39/91 | 42.8 |
| Immune complexes | 2/5 | 40.0 | 31/59 | 52.5 |
| EBV DNA | 1/4 | 50.0 | 14/37 | 37.8 |
| HBV seropositivity | 1/7 | 14.2 | 8/52 | 15.3 |
| HCV seropositivity | 1/7 | 14.2 | 5/52 | 9.6 |
| HTLV-I/II seropositivity* | 1/9 | 11.1 | 16/50 | 32.0 |
| HIV-1/2 seropositivity | 0/6 | 0 | 4/142 | 2.8 |
| Variable . | Patients With Low GL Count . | Typical LDGL Patients . | ||
|---|---|---|---|---|
| . | (<2,000/μL) . | (>2,000/μL) . | ||
| . | Observed . | % . | Observed . | % . |
| Hemoglobin (<10 g/dL) | 5/11 | 45.4 | 37/151 | 24.5 |
| WBC (>5,000/μL) | 1/11 | 9.0 | 126/151 | 83.4 |
| Severe neutropenia | ||||
| (<500/μL) | 4/11 | 36.3 | 55/149 | 36.9 |
| Platelets (<100,000/μL) | 1/11 | 9.0 | 12/134 | 8.9 |
| Bone marrow infiltration | 4/7 | 57.1 | 90/116 | 77.5 |
| Clonal TCR (CD3+ LDGL) | 9/9 | 100 | 115/127 | 90.6 |
| Clonal NK populations (CD3− LDGL) | ND | 12/19 | 63.1 | |
| Cytogenetics abnormality | 0/6 | 0 | 15/119 | 12.6 |
| Coomb's test | 0/6 | 0 | 3/71 | 4.2 |
| Rheumatoid factor | 1/10 | 10.0 | 34/72 | 47.2 |
| Antinuclear antibodies | 3/10 | 30.0 | 23/59 | 38.9 |
| Hypergammaglobulinemia | 3/6 | 50.0 | 39/91 | 42.8 |
| Immune complexes | 2/5 | 40.0 | 31/59 | 52.5 |
| EBV DNA | 1/4 | 50.0 | 14/37 | 37.8 |
| HBV seropositivity | 1/7 | 14.2 | 8/52 | 15.3 |
| HCV seropositivity | 1/7 | 14.2 | 5/52 | 9.6 |
| HTLV-I/II seropositivity* | 1/9 | 11.1 | 16/50 | 32.0 |
| HIV-1/2 seropositivity | 0/6 | 0 | 4/142 | 2.8 |
Abbreviation: ND, not detectable.
The positivity for HTLV-I p19 as reported in the majority of patients is considered indeterminate reactivity and not a true-positive.